RedHill explores opaganib for ebola outbreak response

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to RedHill explores opaganib for ebola outbreak response

RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms

June 2, 2026 8:00 AM EDT

Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma is actively discussing potential collaborations for clinical advancement of opaganib1, including the World Health Organization's (WHO) SOLIDARITY CORE clinical trial platform

Opaganib EVD rationale (analogous to EVD treatment pathway):

Phase 3 clinical antiviral activity (severe COVID-19)... More